Prevalence of treatment resistance and clozapine use in early intervention services by Stokes, Imogen et al.
Prevalence of treatment resistance and clozapine
use in early intervention services
Imogen Stokes*, Siân Lowri Griffiths*, Rowena Jones, Linda Everard, Peter B. Jones, David Fowler,
Joanne Hodgekins, Tim Amos, Nick Freemantle, Vimal Sharma, Max Marshall, Swaran P. Singh,
Max Birchwood† and Rachel Upthegrove†
Background
Treatment resistance causes significant burden in psychosis.
Clozapine is the only evidence-based pharmacologic interven-
tion available for people with treatment-resistant schizophrenia;
current guidelines recommend commencement after two
unsuccessful trials of standard antipsychotics.
Aims
This paper aims to explore the prevalence of treatment resist-
ance and pathways to commencement of clozapine in UK early
intervention in psychosis (EIP) services.
Method
Data were taken from the National Evaluation of the
Development and Impact of Early Intervention Services study
(N = 1027) and included demographics, medication history and
psychosis symptoms measured by the Positive and Negative
Syndrome Scale (PANSS) at baseline, 6 months and 12 months.
Prescribing patterns and pathways to clozapine were examined.
We adopted a strict criterion for treatment resistance, defined as
persistent elevated positive symptoms (a PANSS positive score
≥16, equating to at least two items of at least moderate severity),
across three time points.
Results
A total of 143 (18.1%) participants met the definition of treatment
resistance of having continuous positive symptoms over
12 months, despite treatment in EIP services. Sixty-one (7.7%)
participants were treatment resistant and eligible for clozapine,
having had two trials of standard antipsychotics; however, only
25 (2.4%) were prescribed clozapine over the 12-month study
period. Treatment-resistant participants were more likely to be
prescribed additional antipsychotic medication and polyphar-
macy, instead of clozapine.
Conclusions
Prevalent treatment resistance was observed in UK EIP services,
but prescription of polypharmacy wasmuchmore common than
clozapine. Significant delays in the commencement of clozapine
may reflect a missed opportunity to promote recovery in this
critical period.
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Psychosis is a common, often disabling disorder that occurs at a crit-
ical time in a young person’s development. Despite advances in
mental health treatment, the outcomes for psychosis remain poor
for many.1 A recent meta-analytic review of longitudinal outcomes
in first-episode psychosis (FEP) reported a 38% pooled recovery
rate.2 Other systematic reviews have explored relapse and recovery
rates followingmedication discontinuation in FEP; although there is
a variation in the rates reported across studies (19–89%), the risk of
relapse is significantly reduced by sustained antipsychotic therapy.3–5
These findings have important consequences for the selection of
interventions in FEP.5
Birchwood and colleagues proposed the concept of a ‘critical
period’ in the development and treatment of psychosis,6–8 with sus-
tained and intensive intervention within early intervention in
psychosis (EIP) services potentially improving outcomes.
Adopting an assertive outreach community framework, EIP services
within the UK offer a range of treatment modalities in addition to
psychopharmacology, including psychosocial, vocational and
family interventions to promote recovery.6,9
Such intensive early treatment includes the identification and
active management of early treatment-resistant symptoms. In
England, EIP services are now highly developed and monitored
for the identification of such treatment resistance, which can be
defined as the continued presence of symptoms despite the adequate
trial of two antipsychotic medications, and the offer of clozapine to
individuals who meet these criteria.10,11
Management of treatment resistant psychosis
Although the response rate to antipsychotic medication in the early
phase of psychosis is generally good compared with established
cases,12 clozapine is the only available medication with proven effi-
cacy for patients with treatment-resistant schizophrenia.13,14
Clozapine has superior efficacy in reducing symptom burden and
suicide, and in improving functioning in patients with treatment-
resistant psychosis.15 It is also shown to substantially reduce mortal-
ity rates in individuals with schizophrenia.10 Demjaha et al brought
to light the large proportion of patients who were treatment resist-
ant from the outset of their FEP, and recommended clozapine treat-
ment as early as possible during the first presentation of psychosis.16
However, literature suggests that clinicians are more inclined to pre-
scribe a higher dose of a standard antipsychotic than recommended,
rather than prescribe clozapine.10,15 Furthermore, patients eligible
for treatment with clozapine were found to face delays in com-
mencement of treatment, ranging from 19.3 weeks to 5.5 years.15
Other literature suggests delays in utilising clozapine are even
more extensive; Wheeler carried out a retrospective chart review
of adult out-patients in New Zealand, finding an average duration
of illness of 9.7 years before initiation of clozapine.17 In 2017,
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Doyle et al studied a cohort of patients with FEP and demonstrated
that clozapine was significantly underutilised, yet after the initiation
of clozapine, the mean number of hospital admissions significantly
reduced.18
The present study
The National Evaluation of the Development and Impact of Early
Intervention Services (EDEN) study is the largest cohort study of
young people with FEP, who received care under comprehensive
early intervention services in the UK.19 This paper aims to utilise
this comprehensive, longitudinal study data to present the prescrib-
ing patterns of antipsychotic medication and present the pathways
to, and prescribing of, clozapine for treatment of early treatment-
resistant psychosis.11 Furthermore, this paper aims to explore the
wider prescribing patterns of psychiatrists in UK-based EIP services
in the pharmacologic management of FEP.
Method
Study overview
Data used were from the longitudinal, seven-site UK National
EDEN study. Recruitment concluded in April 2009, with the final
12-month follow-up completed by April 2010.19 Data for this
paper included patient demographics, full medication history and
Positive and Negative Syndrome Scale (PANSS) score.20 Pathways
for those with treatment resistance both with and without clozapine,
and the co-prescribing of other psychotropic mediation (e.g. antide-
pressants), are presented.
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and insti-
tutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008. All procedures
involving human patients were approved by Suffolk Local
Research Ethics Committee, UK (approval number 05/Q0102/44).
Written or verbal informed consent was obtained from all patients.
Verbal consent was witnessed and formally recorded.
Inclusion and exclusion criteria
The National EDEN studies enrolled patients with FEP (ICD-10
diagnosis codes F29, F20, F25, F31, F32.0-F32.1, F32.3 and
F30.221) from early intervention services across England, including
Birmingham, Cornwall, Cambridge, Norwich and Lancashire. As
the study progressed, four other early intervention services were
added into the study to increase the diversity of demographics;
these included Solihull, Cheshire and Wirral, Peterborough and
Kings Lynn. The National EDEN studies included consented
patients aged 14–35 years, with a first presentation of psychosis
symptoms; see Birchwood et al for the full study description.19
Baseline and follow-up measures
The National EDEN study recorded baseline demographics of the
entire cohort (N = 1027), in addition to full medication record.
Severity of psychosis symptoms was measured with the PANSS,
which is a widely used and validated scale.19,20 These measures
were collected at baseline, 6 months and 12 months, by trained
research assistants.
Although there are clear international criteria for remission, the
agreed definitions for treatment resistance in established schizo-
phrenia require repeated episodes and functional impair-
ment.13,22,23 There are no internationally agreed criteria for
treatment resistance after first episode, where diagnoses are more
fluid, and positive symptoms are generally more responsive.24
Therefore, in line with previous literature, we used strict criteria
for persistent positive symptoms (‘treatment resistance’) of a
PANSS positive score ≥16 (equating to at least two positive items
of at least moderate severity) at all three time points, to capture
those participants most likely to be unresponsive to antipsychotic
medication after FEP.16 Those identified as having treatment resist-
ance, and who had been treated with at least two different anti-
psychotic medication, were identified as eligible for clozapine.25,26
Analysis
The prescribing patterns at baseline were explored descriptively to
determine the overall percentage of eachmedication type prescribed
for the full sample (N = 1027). A percentage breakdown of medica-
tion class (e.g. antipsychotic, antidepressant, mood stabilisers and
anxiolytics) was calculated to explore comorbid prescribing within
the cohort. To explore polypharmacy within the treatment-resistant
patient cohort, the full prescribing history from baseline to 12
months was scrutinised; the prescribing history was examined for
co-prescribing of antipsychotics and for co-prescribing of antipsy-
chotics with an antidepressant. The duration of clozapine prescrip-
tions was also examined within the group prescribed clozapine.
Results
Sample
A total of 1027 participants consented to participate in the National
EDEN study, of which 75% (n = 791) were successfully followed up
from study entry to 12-month follow-up, with high retention of data
across clinical measures.19 The full baseline sample had a mean age
of 23 years (s.d. 5.08), 69%weremale and 73%wereWhite. Based on
Operational Criteria Checklist (OPCRIT) criteria,27 the majority of
the sample (47%) had a diagnosis of schizophrenia spectrum dis-
order (ICD-10 diagnosis codes F29, F20 and F25).19 The sample
characteristics for the 791 individuals followed up to 12 months
were as follows: mean age 22.58 (s.d. 4.96), 68.4% male and 74.2%
White (see Table 1). OPCRIT diagnoses were only assessed at
baseline.
A total of 143 participants were identified as treatment resistant
by a continuously raised PANSS positive subscore total of ≥16 at
baseline, 6 months and 12 months. Of these, 61 were eligible for clo-
zapine based on having treatment-resistant symptoms and having
been treated with at least two different antipsychotic medications.
See Table 1 for sample characteristics of the treatment-resistant
groups.
Only 25 participants had been offered a prescription of cloza-
pine by the 12-month time point, including 9 that had been identi-
fied as treatment resistant by the defined criteria, and 16 who had
been started on clozapine where treatment resistance had not
been captured at the follow-up time points. A further 56 partici-
pants were identified as treatment resistant and eligible for cloza-
pine (meeting our criteria for treatment resistance and having
been treated with two or more antipsychotic medications), but
were not prescribed clozapine over the 12-month period.
Prescribing patterns
A total of 1746 individual (psychotropic) medications were pre-
scribed across the full sample (N = 1027) at baseline (Table 2).
There were 1157 prescriptions for antipsychotics (66.3% of all pre-
scriptions), 334 prescriptions for antidepressants (19.1% of all pre-
scriptions), 334 prescriptions for anxiolytics (11.9% of all
prescriptions) and 47 prescriptions for mood stabilisers (2.7% of
all prescriptions), 6 of which of were lithium carbonate (0.3% of
all prescriptions, 12.8% of mood stabiliser prescriptions).
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Analysis of all antipsychotic prescriptions (n = 1157) showed
that the five most commonly prescribed antipsychotics were olanza-
pine (19.4%), risperidone (7.2%), aripiprazole (6.9%), quetiapine
(2.6%) and haloperidol (1.7%). In comparison, clozapine made up
only 0.3% of antipsychotic prescriptions.
Analysis of all antidepressant prescriptions (n = 334) showed
that the five most commonly prescribed antidepressants were cita-
lopram (45.2%), fluoxetine (26.9%), mirtazapine (11.1%), sertraline
(6.9%) and escitalopram (3.3%).
Prescribing in treatment-resistant participants
Analysis of polypharmacy in the treatment-resistant group showed
that, within the 12-month follow-up window, 54 (37.8%) partici-
pants were co-prescribed two antipsychotics, 9 (6.3%) were co-pre-
scribed three antipsychotics and 4 (2.3%) were co-prescribed four
antipsychotics. Moreover, the analysis found that many participants
were co-prescribed antidepressants with an antipsychotic: 57
Table 1 Baseline sample characteristics by treatment group
Full sample at baseline (N = 1027) Non-clozapine group (n = 56) Clozapine group (n = 25) P value
Age at onset
Mean (s.d.) 23 (5.08) 22.93 (5.01) 22.12 (4.89) 0.501
95% CI 21.59–24.27 20.10–24.14
Gender
Male 709 (69.0%) 40 (71.4%) 15 (60.0%)
Female 250 (31.0%) 16 (28.6%) 10 (40.0%) 0.309
Ethnicity
Asian 157 (15.3%) 6 (10.7%) 8 (32.0%)
Black 71 (6.9%) 2 (3.5%) 2 (8.0%)
Mixed 43 (4.2%) 2 (3.5%) 1 (4.0%) 0.132
White 750 (73.0%) 45 (80.4%) 14 (56.0%)
Other 6 (0.6%) 1 (1.8%) 0 (0.0%)
ICD-10 Diagnosis
Unspecified psychosis 203 (19.8%) 10 (17.9%) 6 (24.0%)
Schizophrenia 478 (46.5%) 35 (62.5%) 15 (60.0%)
Schizoaffective 70 (6.8%) 2 (3.5%) 0 (0.0%)
Bipolar affective disorder 19 (1.9%) 5 (8.9%) 1 (4.0%) 0.578
Mania with psychosis 25 (2.4%) 1 (1.8%) 0 (0.0%)
Depressive disorder 91 (8.9%) 0 (0.0%) 0 (0.0%)
Hypomania disorder 10 (1.0%) 0 (0.0%) 0 (0.0%)
Undetermined 131 (12.8%) 3 (5.4%) 3 (12.0%)
Ethnicity, gender and diagnoses in non-clozapine and clozapine groups, compared by chi-squared analysis, with a t-test performed for age.
Table 2 Breakdown of all prescriptions in the study sample
Medication type
Number of
prescriptions
Percentage of
prescribing
Breakdown of prescriptions (n = 1746) from the full study sample (N = 1027)
Antipsychotics 1157 66.3%
Antidepressants 334 19.1%
Anxiolytics 208 11.9%
Mood stabilisers 47 2.7%
Five most commonly prescribed antipsychotic medications (total
prescriptions n = 1157) from the full study sample (N = 1027)
Olanzapine 412 35.6%
Risperidone 339 29.3%
Aripiprazole 125 10.8%
Quetiapine 121 10.5%
Haloperidol 46 4.0%
Other 114 9.9%
Five most commonly prescribed antidepressant medications (total
prescriptions n = 334) from the full study sample (N = 1027)
Citalopram 151 45.2%
Fluoxetine 90 26.9%
Mirtazapine 37 11.1%
Sertraline 23 6.9%
Escitalopram 11 3.3%
Other 22 6.6%
Breakdown of the polypharmacy in the ‘treatment resistant’ (persistently
raised PANSS positive score) group (n = 143)
Co-prescribed two
antipsychotics
54 37.8%
Co-prescribed three
antipsychotics
9 6.3%
Co-prescribed four
antipsychotics
4 2.3%
Co-prescribed an
antidepressant with an
antipsychotic
57 39.9%
Co-prescribed an
antidepressant with two
antipsychotics
15 10.4%
Co-prescribed an
antidepressant with three
antipsychotics
3 2.1%
Co-prescribed an
antidepressant with four
antipsychotics
1 0.7%
PANSS, Positive and Negative Syndrome Scale.
Table 3 Average medication adherence score for the treatment-
resistant group compared with the remaining study sample
Study sample
(non-treatment
resistant), n =
871
Treatment-
resistant
group, n = 156 χ2 P value
Medication adherence, n (%)
Complete
refusal
10 (1.5%) 4 (2.8%)
Partial refusal 31 (4.8%) 10 (6.9%) 9.7 v. 5.5
Accepts only
because it is
compulsory
39 (6.0%) 17 (11.8%) 23.16 0.001
Occasional
reluctance
51 (7.9%) 17 (11.8%)
Passive
acceptance
158 (24.4%) 30 (20.8%)
Moderate
participation
130 (20.1%) 39 (27.1%)
Active
participation
229 (35.3%) 27 (18.8%)
Missing
cases
223 12 – –
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(39.9%) participants were co-prescribed an antidepressant with a
single antipsychotic, 15 (10.4%) were co-prescribed alongside two
antipsychotics, 3 (2.1%) were co-prescribed alongside three antipsy-
chotics and 1 person (0.7%) was co-prescribed an antidepressant
alongside four antipsychotics.
With regards to medication adherence, there was a significant
difference between adherence ratings of the treatment-resistant
group compared with the remaining participants (not identified
as treatment resistant). Less than a quarter of the treatment-resist-
ant group (18.8%) were actively engaged with their treatment, and
9.7% refused (or partially refused) their treatment (Table 3). This
is compared with 35% and 5.5%, respectively, in the remaining
sample (Table 3).
Pathways to clozapine
Participants were trialled on up to five different antipsychotics
before being prescribed clozapine: 4% of patients were not trialled
on an antipsychotic before being prescribed clozapine, 24% were
prescribed after one antipsychotic, 44% were prescribed after two
antipsychotics, 16% were prescribed after three antipsychotics, 8%
were prescribed after four antipsychotics and 4% were prescribed
after five antipsychotics. The mean duration of time spent on cloza-
pine was 5.44 months, and the median duration of clozapine was
5.50 months (see Fig. 1).
Furthermore, before being prescribed clozapine, 4% of patients
were not trialled on a second-generation antipsychotic, 32% were
prescribed one non-clozapine second-generation antipsychotic,
52% were prescribed two different non-clozapine second-gener-
ation antipsychotics, 0% were prescribed three different non-cloza-
pine second-generation antipsychotics and 12% were prescribed
four different non-clozapine second-generation antipsychotics
(see Fig. 1).
Discussion
This data examination has described the prescribing practice and
patterns to clozapine use in a large, national sample of individuals
with FEP, with several findings of note. First, treatment resistance
(here defined as a persistently raised PANSS positive score) is
common in early intervention services, with nearly 20% of indivi-
duals having persistent high levels of symptoms despite intensive
EIP care. Second, despite continuing positive symptoms, a large
number of individuals remain on the same initial medication, and
hence did not meet the eligibility criteria for clozapine treatment.
Of those who were eligible, low numbers were prescribed clozapine.
Second-generation antipsychotics were prescribed for the majority
of FEP individuals, with nearly 20% of antipsychotic prescriptions
at baseline being olanzapine. A total of 39.9% of participants were
co-prescribed an antidepressant with an antipsychotic, and 37.8%
of participants were co-prescribed at least two antipsychotics.
The rates of treatment resistance in our large sample are com-
parable with those found by Demjaha et al, who reported that
23% of patients experiencing FEP were treatment resistant, as
defined by National Institute of Health and Care Excellence
(NICE) guidelines from a sample of 323 participants experiencing
FEP, studied from first contact to 10-year follow-up, from services
across south-east London and Nottingham.16
All participants in the National EDEN study were recruited
from highly concordant, specialist early interventions services,
and this highlights the fact that despite intensive psychosocial inter-
ventions offered as standard in EIP services, treatment resistance
does emerge,19 and may need specialist attention. Notably, some
participants were trialled on up to five antipsychotics before being
prescribed clozapine. These findings indicate a clear stasis in treat-
ment progression, despite patients demonstrating persistent symp-
toms on their current regime. Two longitudinal studies have shown
that of those who were identified as treatment resistant, 70% with
first-episode schizophrenia and 84% with FEP were treatment
resistant from illness onset, highlighting that prompt consideration
of clozapine may be beneficial in this group.28,16
National guidelines and early intervention quality standards
advocate use of clozapine for schizophrenia for illness ‘that has
not improved despite the sequential use of adequate doses of at
least two different antipsychotic drugs’.25 At least one of the drugs
should be a non-clozapine second-generation antipsychotic.26
However, there appears to be a hesitancy to prescribe clozapine
for eligible patients, with only a minority of patients in this
sample prescribed clozapine after being trialled on two different
antipsychotics.
It is apparent from our analysis that clinicians are continuing
ineffective antipsychotics and/or trying augmentation with add-
itional antipsychotics and antidepressants. Thompson et al found
a similar rate (32.6%) of participants received adjunct psychotropic
medications before their prescription of clozapine, despite the lack
of robust evidence for antipsychotic polypharmacy.29 Although data
from Thompson et al and our study is relatively old, since the
National EDEN study data collection concluded in 2012, it
appears that there have not been any significant advances in anti-
psychotic treatments for FEP in this time frame. Recent National
Audit data also does not suggest that clozapine prescriptions are
dramatically improving; among those eligible for clozapine, pre-
scription rates have increased by 5% since 2017.30 It is also interest-
ing to note the common prescription of olanzapine, given both the
considerable side-effect burden, risk of metabolic syndrome and
explicit NICE guidance on the use of olanzapine in young people
under the age of 18 years, which advises that weight and body
mass index monitoring is needed, but not often completed, with
olanzapine.31,32 There is a concern that young people are being
exposed to metabolic risk and being set on the path to metabolic
dysfunction early in the course of psychosis, without sufficient con-
sideration for the longer-term risks.31 Further, given the lack of evi-
dence of a significantly enhanced therapeutic benefit of olanzapine
in FEP,33 the Schizophrenia Patient Outcome Research Team do not
recommend the use of olanzapine as a first-line treatment in FEP.34
It would be speculative to comment on the reasons for such a
low clozapine-prescribing rate in EIP; however, despite their spe-
cialist psychosocial interventions, it is possible that medical man-
agement and clozapine have not featured as prominently as
needed in the development of EIP services. Another potential
barrier to clozapine prescribing in the UK is lack of experience or
knowledge in the initiation of clozapine in the community, which
may be an increased issue in areas of limited in-patient beds. In
2015, Tungaraza and Farooq conducted a survey of 243 consultant
psychiatrists and identified notable knowledge deficits with regard
to the efficacy, risks and benefits of clozapine; results showed that
42.7% of psychiatrists were not aware that clozapine can reduce sub-
stance use, 33% were not aware that the risk of agranulocytosis
changes with time, and 20% were not aware of the benefits of cloza-
pine in reducing risk of suicide.35 Furthermore, there are concerns
regarding the known side-effects of clozapine, such as neutropenia
and potentially fatal agranulocytosis, that are recognised to deter
psychiatrists from prescribing clozapine, especially in community
settings.35,36 Despite these reluctancies, a recent longitudinal study
demonstrated that clozapine use was not associated with higher
risk of severe physical morbidity; in fact, clozapine was associated
with a substantially decreased mortality rate.37
In another survey of clinical staff conducted by Gee et al, the
most commonly stated boundary to clozapine prescribing was
Stokes et al
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perceived concerns regarding patient adherence to blood monitor-
ing.38 Furthermore, the same authors carried out semi-structured
interviews of patients eligible for treatment with clozapine and
43.4% of participants said concerns over adverse effects of clozapine
were considered sufficient grounds to refuse clozapine treatment, but
blood testing was not a significant barrier.39 In addition, 49% of par-
ticipants said they would refuse clozapine if it necessitated a hospital
admission.39 Despite these findings, it is encouraging to note the
efforts in the UK within a newly established, treatment refractory
service for those with schizophrenia. The Treatment Review and
Assessment Team, described by Beck et al, have provided an optimis-
tic framework for prompt clozapine initiation and management in
the community, with preliminary data showing 20 patients per
year are initiated on clozapine, compared with 4 community initia-
tions before the introduction of the service.40
The very limited use of clozapine in the National EDEN study
sample shows that barriers to clozapine prescription exist even in
specialist early psychosis services, and this would be in keeping
with an audit of early intervention services by the Royal College
of Psychiatrists, which found that less than half of patients who
were eligible for clozapine had received the drug.41 Yet there is evi-
dence to suggest that earlier clozapine prescribing may have benefit
in patients experiencing FEP. Lieberman et al performed a 52-week,
randomised controlled trial of clozapine versus chlorpromazine in
treatment-naive patients with first-episode schizophrenia and
found that participants prescribed clozapine showed greater
symptom improvement and earlier remission compared with parti-
cipants prescribed chlorpromazine.42 A follow-up study by Girgis
et al looked at the 9-year outcomes and found that 26.3% of parti-
cipants prescribed clozapine remained on the same treatment, in
contrast to 10% of those prescribed chlorpromazine.43
Sanz-Fuentenbro et al conducted a randomised trial of clozapine
versus risperidone in treatment-naïve patients with first-episode
schizophrenia, with a significant improvement in negative
symptom scores in the clozapine group.44 Agid et al investigated
response to clozapine when utilised in a standardised treatment pro-
gramme in FEP; patients received two trials with two different
second-generation antipsychotics, followed by a trial of clozapine
as early as 25 weeks into the start of their treatment. The results
were highly significant as the group prescribed clozapine demon-
strated significant decreases in symptom scores compared with
those who refused clozapine.45 Finally, a recent retrospective
study of 105 treatment-resistant patients prescribed clozapine
showed the length of clozapine delay (time from diagnosis of treat-
ment resistance to initiation of clozapine) was associated with
outcome, with a delay of >2.8 years having the largest effect.46
This is interesting as it reflects the timescales observed in the critical
period for psychosis literature.6
One finding from our study was that several patients were
chronically unwell, as demonstrated by persistently high PANSS
scores, and yet were not eligible for clozapine by virtue of having
only been prescribed one antipsychotic medication. This may
reflect a lack of focus on the medication management of FEP or a
lack of early recognition of poor prognosis. Although guidelines
currently state that clozapine should be used as a third-line treat-
ment, some authors have made a compelling argument to consider
its use as a second-line treatment, in view of the fall-off in response
to second-line antipsychotic therapy.11,47 Indeed, in a recent large-
scale, three-phase trial of non-response to amisulpride in indivi-
duals with first-episode schizophrenia, Kahn et al demonstrated
no added benefit to outcomes when switching to olanzapine, but
concluded that greater symptomatic remission can be achieved by
sequential administration of amisulpride and clozapine, providing
rationale for the use of clozapine as a second-line treatment.33
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Fig. 1 Pie charts showing the number of antipsychotics and second-generation antipsychotics prescribed before clozapine.
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Taking into consideration the above literature, it is clear there is
a strong emerging evidence base for the use of clozapine in FEP, and
moving forward, it becomes a question of how to implement an
effective action plan to break down the barriers to prescribing clo-
zapine, and ensure that eligible patients receive this efficacious treat-
ment. Improved patient education regarding clozapine, alongside
offering clozapine in the community where appropriate, may
improve patient uptake in the future.39
Study strengths and limitations
There are strengths to this study, including the large sample of 1027
participants enrolled in a national cohort. The National EDEN
study enrolled patients from early intervention services across
England over a 12-month period, making the sample highly repre-
sentative.19 There were robust data collection techniques at baseline,
6 months and 12 months. There are, however, recognised limita-
tions, which include the relatively small number prescribed cloza-
pine and our working definition of ‘treatment resistance’ in FEP.
Treatment adherence was not controlled for during the determin-
ation of treatment resistance, so as to not exclude participants
who were potentially most unwell and further reduce our sample
size. As there was a significant difference in the adherence ratings
between our treatment-resistant group and the remaining EDEN
sample, it is possible that some individuals who were ‘deemed’ treat-
ment resistant may not have met this criterion had they been adher-
ent to their medication regime.3–5 There was a relatively short
follow-up period of 12 months; given that the literature states that
the average duration of illness before initiation of clozapine is
years, rather than months, this may explain the relatively small
number prescribed clozapine in the large sample. Recruitment for
this study concluded in 2009, with the final 12-month follow-up
completed by April 2010; therefore, it is possible that there has
been a shift in prescribing practices in FEP services since this
time, and replication of our findings would be warranted. ICD-10
diagnoses were only available at baseline; had this data been
available at follow-up, it would have given an insight into change
of diagnoses over the 12-month follow-up period. Finally, this
data exploration did not investigate further contextual information,
such as the rates of hospital admission and relapse, or qualitative
data on the barriers to prescribing clozapine in early interventions
services; this would be an area for future exploration.
In conclusion, our data shows that in comprehensive national
FEP services, there were significant delays in commencement of clo-
zapine treatment for potentially eligible patients. Antipsychotic
medication was often not changed despite symptom persistence,
and polypharmacy was more common than use of clozapine. This
may reflect a missed opportunity to influence recovery during the
significant ‘critical period’. Strategies to rectify this issue may
include the increased recognition of early treatment resistance as
a target of therapy, including the development of definitions suitable
for use in FEP services, clinical focus on the initiation of clozapine in
the community, ongoing education of the benefits (including func-
tional recovery and suicide prevention), and further emphasis on
national standards for commencing clozapine in the community.23
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